

Cell Reports, Volume 32

Supplemental Information

Adipocyte Reprogramming

by the Transcriptional Coregulator


GPS2 Impacts Beta Cell Insulin Secretion

Karima Drareni, Raphaëlle Ballaire, Fawaz Alzaid, Andreia Goncalves, Catherine Chollet, Serena Barilla, Jean-Louis Nguewa, Karine Dias, Sophie Lemoine, Jean-Pierre Riveline, Ronan Roussel, Elise Dalmas, Gilberto Velho, Eckardt Treuter, Jean-François Gautier, and Nicolas Venticlef


	Low GPS2 mRNA expression	High GPS2 mRNA expression	<i>p</i>
N	12	11	
GPS2 mRNA expression*	0.30 [0.32]	0.98 [0.51]	<0.0001
Sex: men (%)	75	60	0.65
Age (y)	48 ± 13	48 ± 10	0.96
BMI (kg/m ²)	29.1 ± 2.7	30.8 ± 4.0	0.24
T2DM: N (%)	10 (92)	4 (40)	0.02
HbA1c (%)	7.0 ± 0.5	5.8 ± 0.3	<0.0001
SBP (mmHg)	126 ± 14	122 ± 15	0.52
DBP (mmHg)	82 ± 10	78 ± 10	0.30
Total cholesterol (mmol/l)	4.65 ± 0.96	4.99 ± 1.40	0.49
Triglycerides (mmol/l)	1.16 ± 0.21	1.25 ± 0.86	0.79
Creatinine (μmol/l)	82 ± 17	73 ± 19	0.27

Supplementary Table S1 (Related to Figure 1): Clinical and anthropometric human data.
Mean ± SD or *median [IQR]


A



B




C




**adjusted for sex, age, glycemic status (T2DM or ND), and pre-arginine injection glucose and insulin levels*


Supplementary Figure S1 (Related to Figure 1): (A) Capillary blood glucose, plasma C-peptide and Insulin Secretion Rate (ISR) during a graded glucose infusion. Participants were stratified by GPS2 mRNA expression as Low or High expression as per values below ($n=12$) or above the median ($n=11$), respectively. (B) Glucagon, Insulin and C-peptide levels during a glucose-dependent arginine stimulation by adipocyte GPS2 mRNA expression. (C) Correlation of Acute Insulin Response (AIR) during a glucose-dependent arginine stimulation and adipocyte GPS2 mRNA expression in multivariate analyses. Correlation adjusted for sex, age, glycemic status (T2DM or ND), and pre-arginine injection glucose levels



Supplementary Figure S2 (Related to Figure 2) : (A) RT-qPCR analysis of *GPS2* in eWAT from WT C57BL6/J under High Fat Diet (HFD) during 12 weeks ($n=28$). (B) Area Under the Curve (AUC) of the OGTT of figure 2B and 2C. (C) Index of Insulin resistance (HOMA-IR) of *GPS2* low versus high expression in WAT of high fat fed mice for 12 weeks ($n=9$ in each group). (D) RT-qPCR analysis of *GPS2* in BAT from WT C57BL6/J under High Fat Diet (HFD) during 12 weeks ($n=19$). (E). Oral Glucose Tolerance Test (OGTT) and insulin tolerance test (ITT) in WT C57BL6/J after 12 weeks of HFD classified into 2 groups: high *GPS2* expression ($n=9$) and low *GPS2* expression ($n=10$). (F) Measurements of insulin secretion during the Oral Glucose Tolerance Test in WT C57BL6/J after 12 weeks of HFD classified into 2 groups: high *GPS2* expression ($n=9$) and low *GPS2* expression ($n=9$). (G) RT-qPCR analysis of *GPS2* in eWAT, scWAT, mesWAT, BAT, liver and islets from WT and *GPS* AKO mice on CD ($n=5-6$). All data are represented as mean \pm S.E.M. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.



Supplementary Figure S3 (Related to Figure 2 and 3) : (A) Oral Glucose Tolerance Test (OGTT) in WT controls and GPS2 AKO after CD ,4 and 12 weeks of HFD (CD=4-5, 4 weeks HFD n=6, 12 weeks HFD n= 5-6). (B) Insulin concentration measured during OGTT in in WT controls and GPS2 AKO C57BL6 after CD (n=4-5). (C) Area Under the Curve (AUC) of insulin concentration during the OGTT of figure 2F. All data are represented as mean \pm S.E.M. *P <0.05, ** P <0.01, *** P <0.001. (D) Measurements of islets surface and number and macrophages number in pancreas from WT and GPS2 AKO mice under CD (n=4-5). All data are represented as mean \pm S.E.M. *P <0.05, ** P <0.01, *** P <0.001.



Supplementary Figure S4 (related to Figure 4): (A and B) WAT Gene expression and WAT secretome analysis of mesWAT from WT and GPS2 AKO mice after 12 weeks of HFD (n=4). (C) Glucose Stimulated Insulin Secretion (GSIS) of islets from WT C57BL6/J mice cultured with mesWAT heat inactivated culture medium for 12h and treated for 2 h with low (2.8 mM) or high (16,7 Mm) glucose. Results are expressed in % of insulin content (n=3). (D) Serum concentration of adiponectin (AdipoN), leptin and resistin of WT and GPS2 AKO mice after 12 weeks of HFD (n=6 in each group). (E) Measurement of adipokines and inflammatory genes by RT-qPCR in BAT from WT and GPS2 AKO mice in 12 weeks of HFD (n=5-6). (F) Glucose Stimulated Insulin Secretion (GSIS) of islets from WT C57BL6/J mice cultured with BAT culture medium for 12h and treated for 2 H with low glucose (Low Glc) (2.8 mM) and high glucose (High Glc) (16,7 Mm). All data are represented as mean \pm S.E.M. *P <0.05, ** P <0.01, *** P <0.001.